Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Phathom Pharmaceuticals Inc(PHAT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PHAT
09/25/2026: PHAT (1-star) is currently NOT-A-BUY. Pass it for now.
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the treatment of acid-related gastrointestinal disorders. Its primary asset, VOQUEZNA, introduces a novel P-CAB therapy that offers a clinical alternative to long-standing proton pump inhibitors. The company’s investment story centers on capturing market share in a large, well-established space by demonstrating superior clinical outcomes. Key risks include intense competition from low-cost generic therapies, potential reimbursement hurdles, and the need for sustained commercial execution. The stock may best suit growth-oriented investors with a high tolerance for volatility who are monitoring the pace of adoption and insurance coverage developments for the VOQUEZNA product line.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is in the early stages of a high-growth product launch phase. |
| Momentum investor | Mixed fit | The stock may see momentum swings based on quarterly sales adoption and clinical news. |
| Value investor | Weak fit | The company currently lacks profitability and established earnings metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses capital on growth. |
| Low-risk investor | Weak fit | Biotechnology commercialization carries inherent execution and regulatory risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap biotech stocks often experience significant price swings based on commercial news. |
| Valuation risk | Medium / high | Valuation is highly sensitive to projected future adoption of VOQUEZNA. |
| Competition risk (PPI generics) | High | The existence of low-cost generic competitors makes market share gains challenging. |
| Business quality | Medium | The company is transitioning from development to a commercial-focused business. |
| Dividend income | Low / none | This is a growth-stage company that does not provide income. |
| Execution risk | High | Success depends heavily on physician adoption and insurance coverage for a new drug class. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -36.86% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 590.58M USD | Price to earnings Ratio - | 1Y Target Price 20.45 |
Price to earnings Ratio - | 1Y Target Price 20.45 | ||
Volume (30-day avg) 1.2M shares | Beta 0.51 | 52 Weeks Range 6.91 - 18.31 | Updated Date 09/27/2026 |
52 Weeks Range 6.91 - 18.31 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.27 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Revenue generated from the sale of VOQUEZNA in the United States. | The company generates revenue primarily by selling its specialized acid-suppression medication to wholesalers and pharmacies. |
Valuation
Trailing PE - | Forward PE 6.6 | Enterprise Value 550.13M | Price to Sales(TTM) 2.46 |
Enterprise Value 550.13M | Price to Sales(TTM) 2.46 | ||
Enterprise Value to Revenue 2.3 | Enterprise Value to EBITDA -2.2 | Shares Outstanding 80.90M | Shares Floating 65.29M |
Shares Outstanding 80.90M | Shares Floating 65.29M | ||
Percent Insiders 4.66 | Percent Institutions 92.49 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Phathom Pharmaceuticals Inc
Exchange NASDAQ | Headquarters Florham Park, NJ, United States | ||
IPO Launch date 2019-10-25 | CEO, President & Director Mr. Steven L. Basta M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 371 | Website https://www.phathompharma.com |
Full time employees 371 | Website https://www.phathompharma.com | ||
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.